๐Ÿ“–
Taxifolin targets HMGCR, LDLR and APOB to ameliorate hyperlipidemia: insights from systems pharmacology and nanoemulsion-based delivery.
Alanzi AR, Fatima I, Ashraf MU, Malik MNH, Herqash RN, Abugrain ME, Atif M, Abbas M, Solre GFB

Taxifolin targets HMGCR, LDLR and APOB to ameliorate hyperlipidemia: insights from systems pharmacology and nanoemulsion-based delivery.

Medicine & Health Published 2026 Verification Pending

Overview & Synopsis

Open access biomedical research article published in Open Life Sci.

Advertisement
SPONSOR CONTENT
Indexed from repository: PubMed Central (pmc.ncbi.nlm.nih.gov)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Taxifolin targets HMGCR, LDLR and APOB to ameliorate hyperlipidemia: insights from systems pharmacology and nanoemulsion-based delivery.
Author / Organization Alanzi AR, Fatima I, Ashraf MU, Malik MNH, Herqash RN, Abugrain ME, Atif M, Abbas M, Solre GFB
Subject & Discipline Open Life Sci
Categories Medicine & Health
Publication Year 2026
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website PubMed Central (pmc.ncbi.nlm.nih.gov)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-76662
Original Source Link Visit Source Page on pmc.ncbi.nlm.nih.gov »